Clinical Trial Detail

NCT ID NCT02088112
Title MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors MedImmune LLC
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Gefitinib

Age Groups: adult senior

No variant requirements are available.